Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Clinical Trial ID NCT00151242

PubWeight™ 13.19^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00151242

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.	J Clin Oncol	2011	2.11
2	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.	Blood	2014	1.87
3	Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.	Blood	2009	1.70
4	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.	Haematologica	2008	1.40
5	Inactivating CUX1 mutations promote tumorigenesis.	Nat Genet	2013	1.06
6	Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia.	Leukemia	2012	1.05
7	Retinoid receptor signaling and autophagy in acute promyelocytic leukemia.	Exp Cell Res	2014	0.93
8	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.	Haematologica	2015	0.86
9	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.	Ann Hematol	2016	0.84
10	Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.	Epigenetics	2016	0.75
11	Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.	Leukemia	2016	0.75